Eupraxia Pharmaceuticals, through research and development and collaboration of experts within the medical field (both individuals and enterprise), is discovering, developing, and plans to market innovative technologies for some of society’s most prevalent diseases. The company is advancing the development of a wide portfolio of potential drug and drug delivery system opportunities. Eupraxia intends to provide and continue to build value to its shareholders and to society through the development and marketing of its revolutionary drug and drug delivery platform combination developed in cooperation with its joint venture partner. By joining forces with a company that has a successful history of getting drugs to market Eupraxia is increasing value to shareholders by decreasing risk and making the trajectory of getting the drug to patients more linear and faster.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, has received approval of their Investigational New Drug (IND) application for CT-044 from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed (commence phase I dosing June 2019). CT-044, a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy.

Taiwan Liposome Company (TLC) is a biopharmaceutical company focused on the research, development and commercialization of innovative pharmaceutical products based on its proprietary drug delivery technologies. Our strengths lie in lipid-based formulation and scale-up for parenteral drugs using micelles and nanoparticles to optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs.

Heron Therapeutics is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The company’s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.

Daewoong Pharmaceutical Co., Ltd (Korean: 대웅제약) is a Seoul, South Korea-based bioengineering company operating as a subsidiary of Daewoong Co., Ltd., a global health care group. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products in South Korea, including prescription and over-the-counter healthcare products.

In Therapeutics is a company headquartered in the South Korea. The firm operates a drug development platform.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain. The company was formerly known as AlgoRx Pharmaceuticals, Inc., it changed its name to Anesiva, Inc. in 2006. Anesiva, Inc. was founded in 1999 and is headquartered in South San Francisco, California. On January 15, 2010, Anesiva, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California. On June 10, 2014 filed for Chapter 7 bankruptcy.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

PixarBio Corp. engages in the pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain. It researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson's disease, and spinal cord injury. The company was founded by Frank M. Reynolds, Robert S. Langer, Randy Holmes-Farley and Katrin Holzhaus on August 4, 2014 and is headquartered in Fort Lee, NJ.

Teikoku Pharma USA, Inc. develops and manufactures drugs. It provides patches, unit-dose jellies and liquids, creams, ointments, and other delivery products for pain management and cosmetic care. The company was founded by Masahisa Kitagawa and Ichiro Mori in 1997 and is headquartered in San Jose, CA.

Acclarent, Inc. is a medical device company in Menlo Park, CA that was established in June of 2004. The company is dedicated to the development of innovative devices providing new technologies to further meet the needs of ENT patients. Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplastyâ„¢ devices. Through the Balloon Sinuplastyâ„¢ technology and our RelievaÂ:registered: product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. FDA clearances for these devices were completed in 2005 and the products were commercially launched in the US that same year. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT.

Mochida Pharmaceutical is a drug manufacturing company. Their pharmaceutical business aims to develop and market a broad spectrum of innovative new drugs. They also offer creates skin care products for the general public, and these are supplied through pharmacies, and drugstores.

Part of Medtronic Plc, Covidien Pte Ltd. is a Singaporean company located in Singapore that manufactures and supplies medical equipment.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

JBKLAB Co. Ltd. manufactures cyanidine polysaccharide nano complex. The firm’s offers functional raw materials for drug (raw materials, new drug pipeline) and health functional food, drug and supplement for companion animal and phythochemical fusion health functional food. The company was founded in March 2008 and is headquartered in Gyeonggi-do, South-Korea.

Pacira Pharmaceuticals Inc. operates as a pharmaceutical company which engages in the development and manufacturing of injectable pharmaceutical products. Pacira Pharmaceuticals Inc. was formerly known as DepoTech Corp. was formerly as SkyePharma Inc. and changed its name to Pacira Pharmaceuticals Inc. in June, 2007. The company was founded in 1989 and is based in San Diego, California. Pacira Pharmaceuticals Inc. operates as a subsidiary of Pacira, Inc.